Resistant Bacteria in Children in France

Association Clinique Thérapeutique Infantile du val de Marne1,000 enrolled

Overview

This study is observational, multicenter and prospective study for surveillance of the use of new antibiotics in pediatrics for treated pediatrics infections due to multi-resistant bacteria

The main of this study is to evaluate the relevance of prescribing "new antibiotics" according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation As this is a surveillance study, the clinical and biological characteristics of the children included will be described.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Infection Due to Resistant Bacteria Multi-antibiotic Resistance Antibiotic Prescription Risk Factors Healing Complications Intensive Care Unit

Eligibility

Sex: ALLMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children under 18 years of age * Hospitalized in France in a hospital center working with the ACTIV/GPIP network * Treated with one or more of the following antibiotics: * Colimycin (Colistimethate sodium) * Cefiderocol * Aztreonam in combination * Ceftolozane-Tazobactam * Ceftazidime-avibactam * Meropenem/vaborbactam * Imipenem/Relebactam * Tigecycline * Daptomycin * Ceftaroline fosamil * Tedizolid phosphate * Fidaxomicin * Ceftobiprole * Dalbavancin In association with a documented infection performed by: * Blood culture * Normally sterile site * Cerebrospinal fluid * Pleural fluid * Pleura * Peritoneum * Joint fluid * Other * Urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000) * Respiratory specimens if the bacteria was considered responsible for the infection * Sampling on material such as:Intubation probe, Orthopedic, Urological, Central Nervous System (CNS),.... * Related to colonization with multidrug-resistant bacteria without documentation. Exclusion Criteria: * Refusal of participation by the patient or his/her parent * Medical history of mucoviscidosis

Outcomes

Primary Outcomes

Relevance of prescribing "new antibiotics" according to patient status

Type of new antibiotics prescribed for pediatrics infections caused by multi-resistant bacteria according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation

Time frame: 1 year

Relevance of prescribing "new antibiotics"

how are used new antibiotics prescribed for pediatrics infections caused by multi-resistant bacteria

Time frame: 1 year

Secondary Outcomes

Describe Bacterial epidemiology of infections associated with prescription of new antibiotics

Characteristic of bacteria associated with prescription of new antibiotics

Time frame: 1 year

Identify Risks factors for multi-resistant bacteria

Type of conditions responsible of multi-resistant such as comorbidities, travel, previous hospitalization, previous antibiotherapy,

Time frame: 1 year

Describe Context of drug Prescription

How antibiotics medical prescriptions are controlled and validated

Time frame: 1 year

Department involved in medical prescribing

Number of department involved in medical prescriptions

Time frame: 1 year

Describe Associated Antibiotherapies type

Type of drug association prescribed

Time frame: 1 year

Describe Associated Antibiotherapies

Number of drug association prescribed

Time frame: 1 year

Describe patients outcome

Proportion of patients clinically and bacteriologically recovered

Time frame: 1 year

Resistant Bacteria in Children in France

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts